MedTrace Logo

The Multicentre Selective Lymphadenectomy Trial - 3

NCT07049276 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 1500

Last updated 2026-04-23

No results posted yet for this study

Summary

The goal of this clinical trial is to demonstrate that there is no difference (non-inferiorty) in the 2 year recurrence-free survival (RFS) between 2 different surgical approaches for clinical Stage III melanoma. Following 6 weeks of standard neaodjuvant immunotherapy, patients will undergo either selective index lymph node resection (ILN) (identified at baseline as the largest affected lymph node) or the standard of care therapeutic lymph node dissection (TLND). The secondary aims are to assess if patients who are managed without TLND will have a reduction in surgical complications (less wound problems \& lymphoedema), an improved quality of life, at a lower healthcare utilisation.

Conditions

  • Cutaneous Melanoma, Stage III

Interventions

PROCEDURE

Index lymph node resection

The largest lymph node affected with melanoma

PROCEDURE

Therapeutic lymph node dissection

Removal of all nodes in the melanoma affected lymph node basin

Sponsors & Collaborators

  • Melanoma Institute Australia

    lead OTHER

Principal Investigators

  • Alexander CJ van Akkooi · Melanoma Institute Australia

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-10-01
Primary Completion
2030-08-31
Completion
2040-08-31

Countries

  • United States
  • Australia
  • Canada
  • Italy
  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07049276 on ClinicalTrials.gov